“The alliance between AstraZeneca and Daiichi Sankyo is an excellent example of collaboration. We have learned that teamwork is needed in science to accelerate innovations. In particular, thinking about medical oncology, this is a successful alliance because we have put together human capital, skills, technologies and we also brought to Italy, starting from July 2023, trastuzumab deruxtecan, which belongs to a truly innovative class of drugs, drug-conjugated antibodies, in breast cancer, initially in the Her2 setting -positive (Her2+)”. Thus Alessandra Dorigo, Head of Oncology of AstraZeneca Italia comments, in a meeting with the press in Milan, on the authorization for reimbursement of treatment also in this subgroup of patients for whom, until now, there was only chemotherapy. “Today, a few months later – she underlines – we have this new indication (even in Her2 low patients, i.e. low expression of the Her2 protein, ed.), therefore in another setting of metastatic disease, again in breast cancer”.
“These – continues Dorigo – are just two examples of what we have in development with Daiichi Sankyo. This alliance is an example of excellence, of collaboration, because together we share a great sense of responsibility, not only for cancer patients, but for the entire society. And this sense of responsibility, every day, pushes us to develop and make these innovative treatments accessible as quickly as possible, because we want to make cancer chronic. We also have a great ambition which is to eliminate cancer as a cause of death.”
With trastuzumab deruxtecan “we have 22 active clinical studies – adds Dorigo – not only in breast cancer, but in other settings, including non-metastatic ones, and in other oncotypes, in other solid tumors, which naturally have the expression of the Her receptor 2. We also have another drug in development (datopotamab deruxtecan, ed.). This alliance continues over time, given the great success we have had.” The objective is “to bring together skills, capabilities and all structures, to try to accelerate this research and truly bring these extraordinary innovative drugs – he concludes – as quickly as possible to our patients”.
#Dorigo #AstraZeneca #39alliances #accelerate #innovative #therapies39
